Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Imipenem

FDA-approved product (powder, intravenous).

Registered studies
50+
Lab records
505
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Imipenem
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Endocarditis
  • Infection
  • Pneumonia
  • Sepsis
  • Urinary tract infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Carbapenems
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01DH51

Repurposing investigation

Imipenem is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA62.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli97.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae96.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis31.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 44 of 77 lab records
  • E. coli: measured active in 86 of 94 lab records
  • K. pneumoniae: measured active in 247 of 334 lab records
Open Imipenem in ChEMBL Registered studies below
Show the latest 150 of 505 laboratory records, with sources

Loading records…

Every record is in ChEMBL, linked above. “Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Imipenem with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A De-Escalating Strategy for Antibiotic Treatment of Pneumonia in The Medical Intensive Care Unit (0787B-092)

    NCT00445094 · start 2006-11

    Registered record
    Registry ID
    NCT00445094
    Conditions
    Infection; Pneumonia
    Interventions
    MK0787B, imipenem/cilastatin sodium / Duration of Treatment: 7 Days; Comparator: amikacin / Duration of Treatment: 3 Days; Comparator: tazocin / Duration of Treatment: 3 Days; Comparator: vancomycin / Duration of Treatment: 3 Days
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-11
    Completion
    2007-01
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection; Pneumonia
    InterventionMK0787B, imipenem/cilastatin sodium / Duration of Treatment: 7 Days; Comparator: amikacin / Duration of Treatment: 3 Days; Comparator: tazocin / Duration of Treatment: 3 Days; Comparator: vancomycin / Duration of Treatment: 3 Days
    PhasePhase 4
    Registry statusCompleted

  • Study Comparing Tigecycline and Imipenem/Cilastatin in Chinese Subjects With Complicated Intra-Abdominal Infections

    NCT00136201 · start 2005-11

    Registered record
    Registry ID
    NCT00136201
    Conditions
    Abdominal Abscess
    Interventions
    tigecycline
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-11
    Completion
    2006-12
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAbdominal Abscess
    Interventiontigecycline
    PhasePhase 3
    Registry statusCompleted

  • Complicated Skin and Skin Structure Infections

    NCT00619710 · start 2001-02

    Registered record
    Registry ID
    NCT00619710
    Conditions
    Skin Infection; Abscess; Cellulitis
    Interventions
    Meropenem; Imipenem-cilastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-02
    Completion
    2004-04
    Enrolment
    1,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSkin Infection; Abscess; Cellulitis
    InterventionMeropenem; Imipenem-cilastatin
    PhasePhase 3
    Registry statusCompleted

  • A Study of the Safety and Effectiveness of Levofloxacin Compared With Imipenem/Cilastatin in Patients With Pneumonia Acquired During Hospitalization

    NCT00236834 · start 1997-12

    Registered record
    Registry ID
    NCT00236834
    Conditions
    Nosocomial Pneumonia
    Interventions
    levofloxacin; imipenem/cilastitin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1997-12
    Completion
    2001-06
    Enrolment
    438

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNosocomial Pneumonia
    Interventionlevofloxacin; imipenem/cilastitin
    PhasePhase 3
    Registry statusCompleted

  • Direct E-test on Bronchoalveolar Lavage From Patients With Ventilator-acquired Pneumonia

    NCT01042353

    Registered record
    Registry ID
    NCT01042353
    Conditions
    Ventilator Acquired Pneumonia
    Interventions
    E test; standard culture method
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVentilator Acquired Pneumonia
    InterventionE test; standard culture method
    PhasePhase 4
    Registry statusCompleted